Roche
NEWS
This target date is the latest development in a long series of setbacks that Acadia - and other pharma companies - have experienced getting Alzheimer’s treatments approved.
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
On Wednesday, Massachusetts-based ConforMIS said it was suspending all distribution of its orthopedic medical devices to Russia and any Russian-based entities.
Throughout history, many different countries have had their biopharma supply chains changed – sometimes profitably, sometimes detrimentally – by war.
Jeffrey D. Marrazzo, the co-founder of Spark Therapeutics, is stepping down as CEO of the company. The current COO, Ron Philip, will replace him.
Veru’s enobosarm shows good proof of concept data even when 90% of patients have failed first-line therapies.
The FDA will evaluate AMX0035, an investigational oral fixed-dose drug intended for people diagnosed with ALS.
CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
JOBS
IN THE PRESS
